Results 241 to 250 of about 13,963,189 (308)

Characterizing Cutaneous α‐Synuclein Deposition and Seeding Activity in Parkinson's Disease Subtypes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cutaneous phosphorylated α‐synuclein (p‐syn) and α‐synuclein seeding activity are promising biomarkers for Parkinson's disease (PD), but their clinical value remains uncertain due to disease heterogeneity. This study evaluates these two biomarkers in PD patients to inform phenotype‐specific diagnosis and disease severity assessment ...
Yuting Jin, Tianyuan Yang, Minglei Liu, Haiyang Luo, Jing Yuan, Ke Zhang, Xinsheng Han, Jing Yang, Yuming Xu   +8 more
wiley   +1 more source

Perampanel as a second-line therapy to midazolam reduces soman-induced status epilepticus and neurodegeneration in rats. [PDF]

Epilepsia Open
Steier HG, Schultz CR, Niquet J, Nguyen DA, Stone MF, Biney AK, de Araujo Furtado M, Wasterlain CG, Lumley LA.   +8 more
europepmc   +1 more source

Neurologic Manifestations of Long COVID Affect Adult Females More Severely Than Males

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterize differences in neurologic manifestations of postacute sequelae of SARS‐CoV‐2 infection (Neuro‐PASC) between females and males. Methods Cross‐sectional study of the first consecutive 261 posthospitalization Neuro‐PASC (PNP) and 2068 nonhospitalized Neuro‐PASC (NNP) patients evaluated at the Neuro‐COVID clinic between ...
Hannah Kopinsky, Melissa Lopez, Janet Miller, Millenia Jimenez, Eric M. Liotta, Igor J. Koralnik   +5 more
wiley   +1 more source

Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy

Liver Cancer
Masatoshi Kudo
doaj   +1 more source

Conversion Liver Resection for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Single Tremelimumab Regular Interval Durvalumab Regimen as a Second-Line Therapy: A Case Report. [PDF]

Surg Case Rep
Akhmet D, Soyama A, Kinoshita A, Matsushima H, Imamura H, Hamada T, Satoh A, Migita K, Nakamura S, Askeyev B, Fukushima M, Adachi T, Okano S, Miyaaki H, Eguchi S.   +14 more
europepmc   +1 more source

Quantitative MRI Uncovers Subtle Cortical Damage in Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether myelin‐sensitive quantitative MRI reveals microstructural abnormalities in normal‐appearing cortex (NACtx) in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), indicating that conventional MRI underestimates remission residual cortical injury.
Valentina Camera, Agnese Tamanti, Silvia Messina, Nicola Dall'Osto, Teresa Maltempo, Stefano Ziccardi, Matteo Foschi, Maria Grazia Piscaglia, Diana Ferraro, Francesco Crescenzo, Francesca Rossi, Albulena Bajrami, Sabrina Marangoni, Damiano Marastoni, Francesca Benedetta Pizzini, Maria Isabel Leite, Roberta Magliozzi, Patrick Waters, Massimiliano Calabrese, Jacqueline Palace, Ruth Geraldes   +20 more
wiley   +1 more source

Time-to-Event Modeling for Survival Prediction of Osimertinib as the First- and Second-Line Therapy. [PDF]

J Clin Med
Lee S, Kim H, Lee H, Hahn J, Chang MJ.
europepmc   +1 more source

Cadonilimab as second-line therapy in immunotherapy-resistant squamous NSCLC: a case report and review. [PDF]

Front Immunol
Qiu S, Shi M, Chen Z, Wang J, Cui H, Zhang Y.   +5 more
europepmc   +1 more source

High-Concentration Capsaicin Patch and Oral Pregabalin as Second-Line Therapy for Intercostobrachial Neuralgia After Breast Cancer Surgery: Open-Label Follow-Up of a Multicenter Randomized Controlled Clinical Trial. [PDF]

Cancers (Basel)
Dupoiron D, Bienfait F, Seegers V, Jubier-Hamon S.   +3 more
europepmc   +1 more source

Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure. [PDF]

Dermatol Ther (Heidelb)
Green L, Armstrong A, Han G, Jacobson A.
europepmc   +1 more source